Corrigendum to “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation–positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy” [Lung Cancer 177 (2023) 44–50]

Corrigendum to “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation–positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy” [Lung Cancer 177 (2023) 44–50]

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2024-07, Vol.193, p.107852, Article 107852
Hauptverfasser: Takeda, Masayuki, Shimokawa, Mototsugu, Nakamura, Atsushi, Nosaki, Kaname, Watanabe, Yasutaka, Kato, Terufumi, Hayakawa, Daisuke, Tanaka, Hiroshi, Takahashi, Toshiaki, Oki, Masahide, Tachihara, Motoko, Fujimoto, Daichi, Hayashi, Hidetoshi, Yamaguchi, Kakuhiro, Yamamoto, Shoichiro, Iwama, Eiji, Azuma, Koichi, Hasegawa, Kazuo, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2024.107852